LAG3 and metastatic melanoma: In 2022, the FDA approved the LAG-3 inhibitor, Relatlimab, in combination with nivolumab for the treatment of unresectable or metastatic melanoma in adults and children aged 12 or older, making LAG-3 the third immune checkpoint to be applied in clinical settings after PD-1 and CTLA-4 [153].